Renaissance Technologies (RenTech)'s NKTR Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 41,781 shares of Nektar Therapeutics (NKTR) worth $3.01 M, representing 0.00% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 4 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in NKTR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 31,481 shares. Largest reduction occurred in Q1 2026, reducing 131,100 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Nektar Therapeutics (NKTR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nektar Therapeutics (NKTR) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -131,100 | Reduce 75.83% | 41,781 | $71.95 |
| Q4 2025 | -105,660 | Reduce 37.93% | 172,881 | $42.28 |
| Q3 2025 | +31,481 | Add 12.74% | 278,541 | $56.90 |
| Q2 2025 | +247,060 | New Buy | 247,060 | $25.84 |
Renaissance Technologies (RenTech)'s Nektar Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Nektar Therapeutics (NKTR) in Q2 2025, acquiring 247,060 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Nektar Therapeutics (NKTR) for 4 quarters since Q2 2025.
Renaissance Technologies (RenTech)'s largest addition to Nektar Therapeutics (NKTR) was in Q2 2025, adding 247,060 shares worth $6.38 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 41,781 shares of Nektar Therapeutics (NKTR), valued at approximately $3.01 M.
As of the Q1 2026 filing, Nektar Therapeutics (NKTR) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Nektar Therapeutics (NKTR) was 278,541 shares, as reported at the end of Q3 2025.